Subject(s)
COVID-19 , Pneumonia , Adrenal Cortex Hormones , Humans , Immunosuppressive Agents , Pneumonia/drug therapy , SARS-CoV-2ABSTRACT
OBJETIVOS: Evaluar la seguridad y efectividad en vida real del intercambio en el tratamiento antirretroviral de tenofovir disoproxilo (TDF) a tenofovir alafenamida (TAF) en pacientes VIH. MATERIAL Y MÉTODOS: Estudio retrospectivo observacional durante 2017 en el que se incluyeron todos los pacientes del departamento de salud en tratamiento con TAF. Se evaluó la población obtenida y además se dividió en dos subgrupos no comparativos según el intercambio realizado: subgrupo 1, de elvitegravir/cobicistat/TDF/emtricitabina (EVG/c/TDF/FTC) a EVG/c/TAF/FTC; y subgrupo 2, de TDF/FTC a TAF/FTC. Para la seguridad se midió antes y después del intercambio: creatinina (Cr), urea y velocidad de filtrado glomerular (VFG). Para la efectividad carga viral (CV) y linfocitos CD4. La CV se tomó como variable binaria interpretándose como pacientes respondedores (<20 copias/mL) o no. Las variables numéricas se expresaron en medianas y las cualitativas en porcentaje e intervalo intercuartílico (IQR). Las pruebas utilizadas fueron W de Wilcoxon y chi cuadrado respectivamente. RESULTADOS: Se obtuvo una muestra de 55 pacientes en los que hubo una variación antes y después del cambio de Cr=0,9 mg/dL (IQR=0,8-1) a Cr=0,8 mg/dL (IQR=0,7-0,9) (p < 0,001), de urea=29 mg/dL (IQR = 24-36) a urea = 28 mg/dL (25-34,5) (p = 0,06) y de VFG = 92,8 mL/min (79,3-102,1) a VFG = 103,6 (IQR=95,9-111,1) (p < 0,001). En cuanto a efectividad hubo un incremento desde el 51% al 59,9% (p = 0,821) y para CD4 de 668 CD4/mcL (IQR = 496-824) a 684 CD4/mcL (IQR = 611-807) (p = 0,084). Los resultados por subgrupos fueron similares. CONCLUSIONES: Este estudio muestra en una misma población en vida real, que tras el cambio en la sal de tenofovir se mantiene un buen perfil de seguridad con mejora de parámetros analíticos de la función renal sin perjuicio en la efectividad
OBJECTIVE: To assess safety and effectiveness in real world of the switch in the antiretroviral treatment (ART) of tenofovir disoproxil (TDF) to tenofovir alafenamide (TAF) in HIV patients. MATERIAL AND METHODS: Observational retrospective study during 2017 in which all the patients of the health department under treatment with TAF were included. The population obtained was evaluated and also divided into two non-comparative subgroups according to the switch performed: subgroup 1, from elvitegravir/cobicistat/TDF/emtricitabine (EVG/c/TDF/FTC) to EVG/c/TAF/FTC; and subgroup 2, from TDF/FTC to TAF/FTC. To evaluate safety, before and after the switch, was measured: creatinine (Cr), urea and glomerular filtration rate (GFR). To evaluate effectiveness was measured viral load (VL) and CD4 lymphocytes (CD4). VL was interpreted as binary variable: responder patients (<20 copies/mL) or non-responder patients. Numerical variables were expressed as medians (Md) and qualitative variables as percentage and interquartile interval (IQR). The statistical tests used were W of Wilcoxon and chi square respectively. RESULTS: A sample of 55 patients was obtained. There was a variation, before and after the switch, of Cr=0.9 mg/dL (IQR=0.8-1) to Cr = 0.8 mg/dL (IQR=0.7-0.9) (p < 0.001), from urea=29 mg/dL (IQR = 24-36) to urea=28 mg/dL (IQR = 25-34.5) (p = 0.06) and from GFR = 92.8 mL/min (IQR = 79.3-102.1) to GRT=103.6 (IQR = 95.9-111.1) (p < 0.001). In terms of effectiveness there was an increase from 51% to 59.9% (p = 0.821) responding patients and for CD4 from 668 CD4/mcL (IQR = 446-824) to 684 CD4/mcL (IQR = 611-807) (p = 0.058). The results by subgroups were similar. CONCLUSION: This study showed in real world after the change of tenofovir salt within the same population that a good safety profile is manteined with an improvement of analytical parameters of renal function without affecting its effectiveness
Subject(s)
Humans , Male , Female , Adult , Middle Aged , HIV Infections/drug therapy , Tenofovir/therapeutic use , Antiviral Agents/therapeutic use , Adenine/analogs & derivatives , Tenofovir/adverse effects , Antiviral Agents/adverse effects , Adenine/therapeutic use , Adenine/adverse effects , Retrospective Studies , Viral LoadABSTRACT
OBJECTIVE: The immunosuppressive therapies in the treatment of the immune-mediated inflammatory diseases (EIMI) predispose individuals to the tuberculosis, so the screening of latent tuberculosis infection (ITL) and the treatment reduces the likelihood of a progression to an active tuberculosis. The aim of the study was to analyze the concordance between the test of the tuberculin (PT) and "Interferon Gamma Release Assay-IGRA" in relation to the type of EIMI and the immunosuppressive treatment (IS). METHODS: Transversal study of patients with EIMI candidates or in treatment IS forwarded to the ITL screening, from April 2017 until May 2018. The outcome variables were PT and IGRA. The explicative variables were: EIMI, IS, age, gender, prior BCG vaccination and tuberculosis risk factors. RESULTS: A total of 146 patients were analyzed (33[22.6%] vaccinated with BCG, 1 [0.7%] with a pre-diagnosis of tuberculosis, and 22 [15.1%] from an endemic country). Kappa index (k) was 0,338 between PT and IGRA for the whole sample. A lower concordance was found in patients with the Crohn's disease (k=0.125), in the ones treated with corticosteroids (k=0.222), vaccinated with BCG (k=0.122) and in patients from tuberculosis endemic countries (k=0.128). CONCLUSIONS: The concordance between PT and IGRA is affected in patients with EIMI, and to a greater extent to patients with the inflammatory bowel disease, with the corticotherapy, with the BCG vaccination, or in the ones from endemic countries.
Subject(s)
Immune System Diseases/drug therapy , Immunosuppressive Agents/adverse effects , Interferon-gamma Release Tests , Latent Tuberculosis/diagnosis , Tuberculin Test , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Age Factors , Arthritis, Rheumatoid/drug therapy , BCG Vaccine/administration & dosage , BCG Vaccine/adverse effects , Crohn Disease/drug therapy , Cross-Sectional Studies , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Interferon-gamma Release Tests/statistics & numerical data , Latent Tuberculosis/prevention & control , Male , Middle Aged , Psoriasis/drug therapy , Sensitivity and Specificity , Tuberculin Test/statistics & numerical dataABSTRACT
Eleven cases of gastric carcinoma occurring in patients younger than 30 years were found in a pool of 929 diagnosed in Hospital General de Castelló during the period of 1976 to 1995. Ten patients were male (10/11). The mean age was 26.9 years. In eight cases precancerous lesions were present. The mean time between diagnosis and surgery was 9 months. The most frequent location was the antrum (63.6%) and the most common histology was gastric/diffuse adenocarcinoma of signet-ring cell type (45.5%). Amplified partial gastrectomy was performed in 81.8%, with Billroth II anastomosis in 36.4%. Immediate postoperative mortality rate was 9.1% and the overall mean survival 56 months, being of 54% and 36% at two and five years, respectively.
Subject(s)
Stomach Neoplasms , Adult , Age Factors , Female , Humans , Male , Retrospective Studies , Stomach Neoplasms/pathology , Stomach Neoplasms/therapyABSTRACT
Two cases of non-amyloid light chain deposit disease (EDCL) which were diagnosed by liver biopsy are presented, and the recent literature is reviewed. This disease is a dysproteinemia which shares numerous clinical and pathological features with amyloidosis. A commentary is made on the differential diagnosis between both diseases. This disease must be suspected when the conventional histochemical and immunohistochemical stains for amyloid are negative. Immunohistochemical assays for kappa and lambda chains should then be performed.
